(MENAFN- ProactiveInvestors - UK) Summit Therapeutics PLC''s (LON:SUMM, NASDAQ:SMMT) new antibiotic for Clostridium difficile infection (CDI) has been shown to have further major benefits over the gold-standard treatment.
The ongoing phase II CoDIFy trial of ridinilazole has indicated it is more effective at preserving gut microbiome of patients than the go-to drug vancomycin.
This is important as disruption of the gut microbiome may explain why the infection recurs or some patients don''t have a sustained response to the drugs.
Ridinilazole, which could be used as a broad treatment for CDI, has already demonstrated ''substantial clinical benefit over vancomycin'', including a big reduction in the recurrence of CDI.
The latest data will be presented at a conference called ASM Microbe 2016, which is being held in Boston.
Researcher Dale Gerding, who is Professor of Medicine at Loyola University, Chicago, said: "Ridinilazole is a shining example of translational medicine, where its high selectivity in the lab has read through to a preserved microbiome in trial patients, ultimately resulting in significantly more sustained clinical responses in a phase II trial compared to the standard of care.
"These and additional supporting data presented at ASM Microbe show the broad potential of ridinilazole as a novel treatment for CDI, and I look forward to its continued clinical development."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.